ema prac naion semaglutide june 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Semaglutide Once Again Linked to

drug supply chain, with counterfeit components ranging from dosage and packaging inconsistencies to questionable needles and falsified patient and health care professional information

Cellek, S., Foxwell, N

The 20% reduction was on a combination of three measures

Users should be cautious of gallbladder problems, weight loss benefits, and potential risks like pancreatitis, low blood sugar, and allergic reactions

Science 368(6498):14991504

Phase 2 data suggests retatrutide may produce greater weight reduction than currently approved agents, but its long-term safety profile has not been fully established, and no head-to-head regulatory-grade trials have been completed